B
Brian F. Gage
Researcher at Washington University in St. Louis
Publications - 11
Citations - 9460
Brian F. Gage is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Warfarin & VKORC1. The author has an hindex of 10, co-authored 11 publications receiving 8801 citations.
Papers
More filters
Journal ArticleDOI
Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Brian F. Gage,Amy D. Waterman,William D. Shannon,Michael Boechler,Michael W. Rich,Martha J. Radford +5 more
TL;DR: The 2 existing classification schemes and especially a new stroke risk index, CHADS, can quantify risk of stroke for patients who have AF and may aid in selection of antithrombotic therapy.
Journal ArticleDOI
Estimation of the warfarin dose with clinical and pharmacogenetic data
Teri E. Klein,Russ B. Altman,Niclas Eriksson,Brian F. Gage,Stephen E. Kimmel,Lee Mt,Nita A. Limdi,David C. Page,Dan M. Roden,Michael J. Wagner,Caldwell,Julie A. Johnson +11 more
TL;DR: The use of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin produces recommendations that are significantly closer to the required stable therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach.
Journal ArticleDOI
Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation☆
Brian F. Gage,Amy D. Waterman,William D. Shannon,Michael Boechler,Michael W. Rich,Martha J. Radford +5 more
TL;DR: The 2 existing classification schemes and especially a new stroke risk index, CHADS, can quantify risk of stroke for patients who have AF and may aid in selection of antithrombotic therapy.
Journal ArticleDOI
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Stephen E. Kimmel,Benjamin French,Scott E. Kasner,Julie A. Johnson,Jeffrey L. Anderson,Brian F. Gage,Yves Rosenberg,Charles S. Eby,Rosemary Madigan,Robert B. McBane,Sherif Z. Abdel-Rahman,Scott M. Stevens,Steven H. Yale,Emile R. Mohler,Margaret C. Fang,Vinay Shah,Richard B. Horenstein,Nita A. Limdi,James A.S. Muldowney,Jaspal S Gujral,Patrice Delafontaine,Robert J. Desnick,Thomas L. Ortel,Henny H. Billett,Robert C. Pendleton,Nancy L. Geller,Jonathan L. Halperin,Samuel Z. Goldhaber,Michael D. Caldwell,Robert M. Califf,Jonas H. Ellenberg +30 more
TL;DR: Genotype-guided dosing of warfarin did not improve anticoagulation control during the first 4 weeks of therapy and there was a significant interaction between dosing strategy and race.
Journal ArticleDOI
CYP4F2 genetic variant alters required warfarin dose.
Michael D. Caldwell,Tarif Awad,Julie A. Johnson,Brian F. Gage,Mat Falkowski,Paul Gardina,Jason Hubbard,Yaron Turpaz,Taimour Y. Langaee,Charles S. Eby,Cristi R. King,Amy Brower,John R. Schmelzer,Ingrid Glurich,Humberto Vidaillet,Steven H. Yale,Kai Qi Zhang,Richard L. Berg,James K. Burmester +18 more
TL;DR: A novel variant in cytochrome P450 4F2 (CYP4F2) was associated with warfarin dose in 3 independent white cohorts of patients stabilized on war Farfarin representing diverse geographic regions in the United States and accounted for a difference in warFarin dose of approximately 1 mg/day between CC and TT subjects.